UK markets closed

RedHill Biopharma Ltd. (RDHL)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4317-0.0023 (-0.53%)
As of 01:27PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 13.80M
Enterprise value 9.40M
Trailing P/E 0.11
Forward P/E 1.43k
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.43
Price/book (mrq)6.67
Enterprise value/revenue 1.44
Enterprise value/EBITDA 0.36

Trading information

Stock price history

Beta (5Y monthly) 3.46
52-week change 3-79.86%
S&P500 52-week change 324.19%
52-week high 33.2800
52-week low 30.2570
50-day moving average 30.5038
200-day moving average 30.8005

Share statistics

Avg vol (3-month) 3588.95k
Avg vol (10-day) 3384.14k
Shares outstanding 531.87M
Implied shares outstanding 611.07M
Float 87.42B
% held by insiders 10.00%
% held by institutions 16.25%
Shares short (15 Apr 2024) 4741.45k
Short ratio (15 Apr 2024) 41.79
Short % of float (15 Apr 2024) 42.61%
Short % of shares outstanding (15 Apr 2024) 42.33%
Shares short (prior month 15 Mar 2024) 41.06M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:40
Last split date 323 Mar 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 366.25%
Operating margin (ttm)-1,060.79%

Management effectiveness

Return on assets (ttm)-15.71%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)6.53M
Revenue per share (ttm)1.01
Quarterly revenue growth (yoy)-95.60%
Gross profit (ttm)N/A
EBITDA -22.15M
Net income avi to common (ttm)23.92M
Diluted EPS (ttm)4.0000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)5.57M
Total cash per share (mrq)0
Total debt (mrq)1.17M
Total debt/equity (mrq)56.69%
Current ratio (mrq)0.84
Book value per share (mrq)0.10

Cash flow statement

Operating cash flow (ttm)-35.82M
Levered free cash flow (ttm)-18.23M